Core Viewpoint - The company announced that its wholly-owned subsidiary, Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., has received a drug registration certificate for the balanced salt irrigation solution from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][4]. Group 1: Drug Registration Certificate - The balanced salt irrigation solution is a sterile electrolyte solution suitable for surgical irrigation [1]. - The research and development of this drug began in January 2022, with the application for market approval submitted in April 2024 and the approval granted in February 2026 [1][2]. Group 2: Market Situation - The balanced salt irrigation solution was developed by ICU MEDICAL INC and was approved for sale in the U.S. in February 1978 under the brand name "Physiosol." It has not been marketed in China [3]. - In 2024, the global sales of balanced salt irrigation solutions are projected to be approximately $3.34 million [3]. - In the Chinese market, there are 10 approved manufacturers of balanced salt irrigation solutions, with only 3 having passed or been deemed to have passed the consistency evaluation, including Jingxi Shuanghe [3]. Group 3: Financial Investment - The total R&D investment for the balanced salt irrigation solution has reached approximately RMB 3.65 million (unaudited) [2].

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Xi'an Jingxi Double Crane Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for balanced salt irrigation solution from the National Medical Products Administration [2] Group 1 - The announcement highlights the regulatory approval for a new pharmaceutical product, indicating a positive development for the company's product portfolio [2] - The balanced salt irrigation solution is likely to enhance the company's offerings in the medical and pharmaceutical market, potentially leading to increased revenue [2]

Group 1 - Company announced that its wholly-owned subsidiary, Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., received a drug registration certificate for "Balanced Salt Irrigation Solution" from the National Medical Products Administration [1] - The product name is "Balanced Salt Irrigation Solution" [1] Group 2 - The news highlights a significant event in the real estate sector, where over 100,000 people overwhelmed servers to witness eight real estate companies compete for a "racecourse," resulting in 243 rounds of bidding over 9 hours, with a total transaction value of 23.6 billion yuan [1] - A new land price record was set in Guangzhou, with a floor price of 85,000 yuan per square meter [1]

Group 1 - The core point of the article is that China Resources Double Crane Pharmaceutical Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its balanced salt irrigation solution, which is a sterile electrolyte aqueous solution suitable for surgical irrigation [1] Group 2 - The product, balanced salt irrigation solution, is specifically designed for use in surgical procedures [1]

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its balanced salt irrigation solution, indicating a significant regulatory approval for the company’s product line [1] Group 1: Company Developments - The wholly-owned subsidiary of China Resources Double Crane, Xi'an Jingxi Double Crane Pharmaceutical Co., Ltd., is responsible for the newly approved balanced salt irrigation solution [1] - The balanced salt irrigation solution is a sterile electrolyte aqueous solution, which is suitable for surgical irrigation, expanding the company's product offerings in the medical field [1]

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Jingxi Double Crane, received the Drug Registration Certificate for the balanced salt irrigation solution from the National Medical Products Administration, allowing it to be marketed [1] Group 1: Product Development - The drug is a sterile electrolyte solution suitable for surgical irrigation and is considered to have passed the consistency evaluation [1] - Research and development for this product began in January 2022 and received approval in February 2026 [1] - Cumulative R&D investment reached 3.6531 million yuan as of the announcement date [1] Group 2: Market Potential - The global sales forecast for the drug in 2024 is approximately 3.3442 million USD, while the total domestic market sales are projected to be 55.85 million yuan [1] - The approval of this drug will enrich the company's product line and enhance its competitiveness [1] - However, there is uncertainty regarding the sales performance of the product [1]